Amgen Inc. will collaborate with San Francisco-based Syapse, a precision medicine company, to further oncology research, according to a statement from the Thousand Oaks company.

Under terms of the agreement, Amgen and Syapse will develop research analytics to assess treatment outcomes for certain types of cancer. Patients within the Syapse Learning Health Network may be eligible for Amgen-sponsored clinical trials.

Physicians and researchers within the Syapse network will have access to Amgen’s analytics, insights and collaborative research opportunities, while Amgen representatives will be able to use Syapse’s real-world evidence in regulatory filings.

“Our collaboration with Syapse supports … leveraging real-world evidence to accelerate bringing new oncology treatments to market and empowers health care providers with more robust insights and decision-making tools to improve patient care,” Mike Nohaile, senior vice president of strategy, commercialization and innovation at Amgen, said in a statement.

The company announced the partnership on Thursday. Shares of Amgen (AMGN) closed Monday down 25 cents, or 0.14 percent, to $177.06 on the Nasdaq.